This Month in JNM

July 1, 2019

Discussions with leaders—JNM contributor Ken Herrmann conducts a wide-ranging interview on leadership issues in nuclear and molecular imaging and therapy with Susanne Schaffert of Novartis Oncology. Page 875

Hot Topics—CAR T-cell oncologic imaging: Krebs and colleagues provide an overview of cancer immunotherapy based on targeted approaches using chimeric antigen receptor T-cells, including cell tracking, clinical imaging, imaging models, novel constructs, and real-time applications. Page 879

State of the Art—Theranostics in G3 NENs: Waseem and colleagues review the current state of the art in somatostatin receptor theranostics for grade 3 neuroendocrine neoplasms, with special foci on histologic classification and choice of diagnostic imaging approach. Page 882

Cardiac sarcoidosis imaging: Ramirez and colleagues provide an educational overview of current theoretic and practical aspects of cardiac imaging, including PET and MRI, in evaluation of patients with suspected or established cardiac sarcoidosis. Page 892

Immuno-PET in mAb therapy: Reilly offers perspective on current clinical development pathways for monoclonal antibody therapies and previews an article in this issue of JNM on immuno-PET in patients with human epidermal growth factor receptor 3–positive tumors. Page 899

Featured Article of the Month—89Zr-Anti-HER3 mAb immuno-PET: Menke-van der Houven van Oordt, McGeoch, and colleagues investigate biodistribution and uptake of 89Zr-labeled GSK2849330, an anti–human epidermal growth factor receptor 3 monoclonal antibody, and evaluate target engagement as a function of antibody mass dose. Page 902

Featured Translational Science Article—CTT1057 in PCa: Behr, Aggarwal, and colleagues detail a first-in-humans phase I study of CTT1057, an agent based on a phosphoramidate scaffold that irreversibly binds to prostate-specific membrane antigen, in patients with localized and metastatic prostate cancer. Page 910

MEK inhibitor–induced 131I uptake: ElMokh and colleagues target the mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in in vitro studies and a murine model to induce radioiodine uptake for treatment of anaplastic thyroid carcinoma. Page 917

18F-DMFB for melanoma: Pyo and colleagues synthesize a novel 18F-labeled benzamide derivative with high melanin-targeting ability and evaluate its biologic characteristics in small animal models of malignant melanoma. Page 924

P2X7 radioligand PET probe: Fu, Lin, and colleagues evaluate the potential value of 18F-PTTP for targeting P2X7 receptors to differentiate inflammation from tumors, quantify peripheral inflammation, and screen new drugs. Page 930

177Lu-DOTATATE in GEP NETs: Hope and colleagues provide practical guidance on treatment of patients with gastroenteropancreatic neuroendocrine tumors using somatostatin receptor–based peptide receptor radionuclide therapy with 177Lu-DOTATATE, based on recent consensus guidelines. Page 937

PET/CT and MRI in PCa detection: Chen, Zhang, Zhang, and colleagues explore the question of whether 68Ga–prostate-specific membrane antigen PET/CT alone or in combination with multiparametric MR imaging can improve detection of clinically significant prostate cancer. Page 944

Androgen blockade and PSMA PET: Emmett and colleagues evaluate the effect of androgen blockade treatment on 68Ga–prostate-specific membrane antigen–11 PET imaging in hormone-naive and castrate-resistant men with metastatic prostate cancer. Page 950

177Lu-PRLT in metastatic PCa: Barber, Singh, and colleagues assess clinical outcomes in 177Lu–prostate-specific membrane antigen–targeted therapy in taxane chemotherapy–pretreated and –naïve patients with metastatic castration-resistant prostate cancer. Page 955

PSMA PET/CT vs. CT in PCa: Schmidt-Hegemann and colleagues report on a retrospective study determining the comparative effects of 68Ga–prostate-specific membrane antigen PET/CT and standard CT-based imaging on radiotherapeutic approaches to prostate cancer. Page 963

PET in PCa LN metastases: Jilg and colleagues use 18F-choline and 68Ga–prostate-specific membrane antigen PET/CT before lymphadenectomy in prostate cancer to determine relationships between lymph node metastatic rate and size of tumor deposits in metastases. Page 971

SVCA and 11C-PBR28: Zanotti-Fregonara and colleagues test a supervised clustering algorithm in Alzheimer disease, mild cognitive impairment, and controls injected with the translocator protein 11C-PBR28 and compare kinetic modeling results obtained with those from arterial input function. Page 978

Efflux enhancement by ABCB1: Tournier, Bauer, and colleagues perform PET with the weak P-glycoprotein substrate 11C-metoclopramide in humans to elucidate the effect of ABCB1 function on its brain kinetics. Page 985

Brain BACE1 in NHPs: Takano and colleagues quantitatively evaluate regional brain distribution of 18F-PF-06684511 under baseline and blocking conditions, assess target occupancy of β-secretase 1 inhibitors in nonhuman primates, and use whole-body PET to estimate effective radiation doses. Page 992

PET/CT in bacteremia treatment: Berrevoets and colleagues investigate the safety of a shorter duration of treatment in patients with high-risk Staphylococcus aureus bacteremia without signs of metastatic infection, determined by 18F-FDG PET/CT and echocardiography. Page 998

Toward novel 18F-amino acids tracers: Nodwell and colleagues examine in in vitro and in vivo studies the structure–activity relationships of a series of 18F-labeled amino acids predicted to be substrates of the large, neutral L-type amino acid transporter system. Page 1003

Improved minigastrin for theranostic use: Klingler and colleagues present a new minigastrin analog, DOTA-MGS5, with site-specific C terminus modifications showing a highly optimized targeting profile and promise in cholecystokinin-2 receptor–expressing malignancies. Page 1010

18F-AlF-PSMA-11 PET/CT: Lütje and colleagues compare the prostate-specific membrane antigen (PSMA)–targeting characteristics of PSMA-11, radiolabeled on the basis of chelation of 18F-AlF, with those of 68Ga-PSMA-11 in imaging PSMA-expressing xenografts. Page 1017

Visualization of KOR active state: Li and colleagues report on development and evaluation of 11C-EKAP, compare it with 11C-GR103545 in PET imaging of κ opioid receptors in nonhuman primates, and describe the new tracer’s potential in theranostic applications. Page 1023

Vision PET/CT system: Sluis and colleagues report on the performance of the Biograph Vision digital PET/CT system according to the NEMA NU 2-2012 standard for reliability, reproducibility, and intersystem comparability. Page 1031